JP2002517181A - 細胞の活性化を調節するために提供される核酸 - Google Patents

細胞の活性化を調節するために提供される核酸

Info

Publication number
JP2002517181A
JP2002517181A JP2000530601A JP2000530601A JP2002517181A JP 2002517181 A JP2002517181 A JP 2002517181A JP 2000530601 A JP2000530601 A JP 2000530601A JP 2000530601 A JP2000530601 A JP 2000530601A JP 2002517181 A JP2002517181 A JP 2002517181A
Authority
JP
Japan
Prior art keywords
nucleic acid
cells
rsk3
dna
mrna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000530601A
Other languages
English (en)
Japanese (ja)
Inventor
ヒンリッヒ・アップケン
Original Assignee
キュラサイト・アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1998138967 external-priority patent/DE19838967A1/de
Priority claimed from DE1998159056 external-priority patent/DE19859056A1/de
Application filed by キュラサイト・アクチェンゲゼルシャフト filed Critical キュラサイト・アクチェンゲゼルシャフト
Publication of JP2002517181A publication Critical patent/JP2002517181A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2000530601A 1998-02-06 1999-02-05 細胞の活性化を調節するために提供される核酸 Pending JP2002517181A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE1998138967 DE19838967A1 (de) 1998-02-06 1998-02-06 Verfahren zur Hemmung der unbegrenzten Proliferation, Tumorbildung oder Metastasierung CD30 Antigen exprimierender Zellen
DE19838967.1 1998-12-22
DE19859056.3 1998-12-22
DE1998159056 DE19859056A1 (de) 1998-12-22 1998-12-22 Nukleinsäuren zur Modulation zellulärer Aktivierung
PCT/EP1999/000759 WO1999040187A1 (fr) 1998-02-06 1999-02-05 Acides nucleiques pour la modulation de l'activation cellulaire

Publications (1)

Publication Number Publication Date
JP2002517181A true JP2002517181A (ja) 2002-06-18

Family

ID=26048423

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000530601A Pending JP2002517181A (ja) 1998-02-06 1999-02-05 細胞の活性化を調節するために提供される核酸

Country Status (3)

Country Link
EP (1) EP1053316A1 (fr)
JP (1) JP2002517181A (fr)
WO (1) WO1999040187A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6652854B2 (en) * 2000-08-08 2003-11-25 Immunex Corporation Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
MXPA04006490A (es) 2002-01-09 2005-06-08 Medarex Inc Anticuerpos monoclonales humanos contra cd30.
WO2006039644A2 (fr) 2004-10-01 2006-04-13 Medarex, Inc. Procede pour traiter des lymphomes positifs cd30
RU2492186C2 (ru) 2005-02-18 2013-09-10 Медарекс Ллс Выделенное анти-cd30 антитело (варианты), хозяйская клетка, способ получения химерного или гуманизированного варианта анти-cd30 антител (варианты), способ ингибирования роста клеток cd30+ и способ ингибирования роста опухолевых клеток, экспрессирующих cd30
RU2650800C2 (ru) 2012-04-27 2018-04-17 Ново Нордиск А/С Белки, связывающие антиген - лиганд cd30 человека

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6909191A (en) * 1989-11-20 1991-06-13 Parker, David L. Improved cd-30 antibodies and fragments thereof
DE4200043A1 (de) * 1991-11-11 1993-05-13 Stein Harald Prof Dr Lymphoides cd30-antigen (ki-1), dessen protein- und die zugehoerige nucleotidsequenz, seine herstellung sowie mittel zur diagnose und untersuchung von tumoren
WO1993024135A1 (fr) * 1992-05-26 1993-12-09 Immunex Corporation Nouvelle cytokine de fixation sur cd30
US5516679A (en) * 1994-12-23 1996-05-14 Bristol-Myers Squibb Company Penicillin V amidohydrolase gene from Fusarium oxysporum
DE19640733A1 (de) * 1996-10-02 1998-04-09 Abken Hinrich Verfahren zur Hemmung der unbegrenzten Profileration, Tumorbildung oder Metastasierung CD30 Antigen exprimierender Zellen

Also Published As

Publication number Publication date
EP1053316A1 (fr) 2000-11-22
WO1999040187A1 (fr) 1999-08-12

Similar Documents

Publication Publication Date Title
CN106061488B (zh) 癌症的免疫治疗
US9186373B2 (en) SiRNA against Cbl-b and optionally IL-2 and IL-12 for use in the treatment of cancer
KR20000069658A (ko) Ｇ 풍부 올리고 앱태머 및 면역 반응을 변조시키는 방법
WO2015096659A1 (fr) Utilisation d'inhibiteur de miarn-214 pour inhibition de cellules t régulatrices
WO2010026660A1 (fr) Arn capable d'inhiber l'expression du gène zfat
JP2022512922A (ja) キメラ抗原受容体記憶様（ｃａｒｍｌ）ｎｋ細胞ならびにその産生および使用方法
US20020091095A1 (en) Modulation of Fas and FasL expression
JP2002517181A (ja) 細胞の活性化を調節するために提供される核酸
JPH08506087A (ja) ガン処置のための抗腫瘍薬とアンチセンスオリゴヌクレオチドの組み合わせ
KR20190128674A (ko) Masp2의 발현을 억제하는 핵산
CN113227384A (zh) 用于治疗肿瘤的药物组合物、药盒和方法
WO2018224615A1 (fr) Procédés et compositions pour le traitement de troubles de l'hyperpigmentation
WO1996024380A9 (fr) Methodes et compositions de regulation de l'expression de cd28
WO1996024380A1 (fr) Methodes et compositions de regulation de l'expression de cd28
Meye et al. Colony formation of soft tissue sarcoma cells is inhibited by lipid-mediated antisense oligodeoxynucleotides targeting the human mdm2 oncogene
EP3101133B1 (fr) Expression en tandem d'arnsi et ses utilisations dans le traitement de la leucémie lymphoïde chronique
US8242094B2 (en) siRNA of NF-kB p105 for inhibiting cell proliferation and migration and a composition comprising same
KR100258826B1 (ko) Cd28 발현의 조절을 위한 방법 및 조성물
EP1313853B1 (fr) Modulation de l'expression de fas et fasl par un oligonucléotide phosphodiester synthétique et un anticorps anti-fas
AU2006235868B2 (en) Reversible immortalization
CN118086406A (zh) 一种sept7基因敲除的car-t细胞及制备方法与应用
CN113337505A (zh) 人工构建的反义核苷酸片段Ri111在Th1细胞极化中的应用
DE19859056A1 (de) Nukleinsäuren zur Modulation zellulärer Aktivierung
AU2001268863B2 (en) Modulation of FAS and FASL expression
JPH11285391A (ja) 抗ｈｉｖ剤